Introduction: Liver cirrhosis develops in about 10% of alcohol abusers. To date, a number of
Introduction
Chronic alcohol abuse can lead to the development of alcoholic liver disease, chronic pancreatitis and many other ailments. Liver cirrhosis is a relatively common disease; its incidence is estimated at 200-300 per 100 000 individuals. In Poland, the liver cirrhosisassociated mortality increased from 5.14/100 000 in 1980 to 7.6/ 100 000 inhabitants in 2010 The aim of the present study was to determine serum concentrations of afamin and adropin in patients with alcoholic liver cirrhosis and to define their correlation with the stage of disease.
Material and methods

Patients
The study included 99 patients with alcoholic cirrhosis from the region of Lublin, (Eastern Poland). Liver cirrhosis was diagnosed based on clinical features, history of heavy alcohol consumption, laboratory tests and abdominal ultrasonography. The patients with alcoholic hepatitis, hepatocellular carcinoma, viral and autoimmune diseases were excluded from the study. Other exclusions criteria were: type 2 diabetes, obesity, acute infections (e.g., pneumonia, spontaneous bacterial peritonitis), acute and chronic heart failure (> NYHA I), acute and chronic respiratory disorders resulting in respiratory insufficiency, acute kidney injury and chronic kidney disease (> stage G2). Both clinical assessment and laboratory tests were used to exclude the underlying liver diseases in the control group. The degree of liver cirrhosis was evaluated according to the Pugh-Turcotte-Child criteria (Pugh-Child score) viii .
Based on them patients were assigned to one of three groups: Pugh-Child (P-Ch) A -29 with stage A , P-Ch B -26 with stage B and P-Ch C -34 with stage C of liver cirrhosis. The control group consisted of 20 healthy individuals without liver disease who did not abuse alcohol. There were no significant age-or gender-related differences in the groups (Table 1) .
Detailed demographic, clinical and biochemical characteristics of patients are presented in Table 1 and 2.
The study protocol was approved by the Ethics Committee. All subjects gave their written informed consent for participation in the study.
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Determination of serum afamin concentration
The afamin concentration was determined using human afamin ELISA kit (BioVendor, Czech Republic) according to the manufacture's procedure. After the addition of the appropriately diluted samples (100-fold diluted serum), standards and water (blank sample), 60-minute incubation was provided. During incubation, human afamin was bounded to antibodies absorbed to the microwells. After incubation and washing, monoclonal antihuman afamin antibody conjugated with horseradish peroxidase (HRP) was added to the wells and incubated for 60 minutes with captured afamin. After a thorough wash, the remaining conjugate was allowed to react with the substrate solution (TMB). The reaction was stopped by addition of acidic solution. Absorbance of coloured products was measured spectrophotometrically (λ=450 nm) and their concentration was determined using a standard curve prepared for standards. The results were multiplied by a dilution factor (100).
Determination of serum adropin concentration
Adropin concentration was determined using sandwich enzyme immunoassay kit for adropin (Cloud Clone Corp., Katy, TX, USA) according to the manufacturer's procedure.
Samples (20-fold diluted serum), standards and water (blank sample) were applied onto a microtiter plate pre-coated with an antibody specific to adropin. After 60 minutes of incubation the content of the wells was removed, the plate was washed and a biotinconjugated antibody specific to adropin was added. Next, Avidin conjugated to horseradish peroxidase (HRP) was added to each microplate well and incubated. During the next step, TMB substrate solution was added to each well. In the wells containing adropin, biotinconjugated antibody and enzyme-conjugated Avidin exhibited a colour change. The enzymesubstrate reaction was terminated by addition of sulphuric acid solution and the absorbance of standards and samples was measured spectrophotometrically at a wavelength 450nm. The concentration of adropin in the samples was determined using a standard curve constructed for standards. The results were multiplied by a dilution factor (20) .
Statistical analysis
STATISTICA 13 (Statsoft, Inc.) was used for data analysis. Continuous variables were expressed as the mean ± standard deviation (SD 
Results
The concentration of afamin was found to be significantly lower in patients with compensated alcoholic liver cirrhosis, i.e. P-Ch B (85.1±40.6 μg/ml) and P-Ch C (56.4±32.3 μg/ml) individuals, as compared to the control group (135.9±43.6 μg/ml); p-value was <0.01 and <0.001, respectively. Moreover, a significant difference in the concentration of afamin was observed between patients with P-Ch stage C and P-Ch stage A of disease (124.8±72.4 μg/ml); p-value was <0.01) ( Figure 1A ).
As far as adropin is concerned, a reverse relationship was demonstrated: the highest concentration was found in patients with P-Ch C (11.7±5.7 ng/ml) cirrhosis. Furthermore, the above concentration was significantly higher compared to patients with P-Ch A cirrhosis (7.2±2.8 ng/ml; p<0.05) and controls (7.5±2.6 ng/ml; p<0.05) ( Figure 1B ).
To evaluate the independent effects of various variables on the concentration of afamin and adropin, a multiple linear regression analysis was performed. The following variables were used: stage of disease according to the P-Ch classification and the additional laboratory parameters outside this classification. The factors independently associated with serum concentrations of afamin were found to be: stage of liver cirrhosis according to the PCh score (the highest relative effect on the variability of afamin concentration), activity of ASP and concentration of urea. This model accounted only for 15% of variability of an independent variable albeit was optimal under given conditions (Table 4 ).
In the case of adropin, the regression model contained only two independent variables:
stage of cirrhosis according to the P-Ch score and concentration of CRP. The model accounted for 17% of variability of serum adropin concentration and the highest relative effect on this variability was attributable to the stage of disease according to the P-Ch score (Table 5) .
Receiver-operators characteristic (ROC) curves used for diagnostic accuracy of afamin and adropin are given in Figure 2 .
Discussion
In our study, the plasma concentration of afamin was found to decrease with the degree of severity of alcoholic liver cirrhosis. . Otherwise, no changes in concentrations of afamin were observed in patients with chronic obstructive pulmonary disease (COPD) and chronic renal disease. In cases of heart failure, concentrations of afamin were only slightly reduced [Dieplinger 2015 ]. According to literature data, the concentration of afamin has been reversely correlated with the concentration of C-reactive protein (CRP) and of interleukin-6 xiv . Therefore, afamin is considered a negative acute phase protein.
To the best of our knowledge, our study is the first to focus on determinations of plasma concentrations of afamin in patients with alcoholic liver cirrhosis. Our findings demonstrated reduced serum concentrations of afamin in patients with alcoholic liver cirrhosis. The higher the stage of the disease, the lower the concentrations of afamin.
However, contrary to the other groups of patients, CRP was not found to be an independent predictor of afamin concentrations. In the multi-factorial model, the variability of afamin concentrations was most strongly affected by the Pugh-Child category, which can be explained by impaired anabolic function of the liver during cirrhosis. The above is analogical to hypoalbuminaemia observed in cirrhosis-related renal failure when concentrations of albumins are reduced, their structure is impaired and they are excessively intravascularly The available literature lacks studies on the role of adropin in liver cirrhosis. In our study, the concentration of adropin was positively correlated with the stage of liver cirrhosis according to the Pugh-Child score. Additionally, in the multifactorial model, an independent factor associated with the level of adropin was C-reactive protein. Nevertheless, the model designed accounted only for 17% of variability of the dependent variable and thus cannot be used for prognostic purposes.
Considering the complex nature of metabolic disorders in compensated liver cirrhosis, it cannot be excluded that elevated adropin concentrations noted in our study resulted from feedback mechanisms leading to increased extra-hepatic synthesis.
Receiver-operator characteristic (ROC) curves showed that adropin is not a valuable diagnostic marker for alcoholic cirrhosis. On the other hand, afamin is characterized by relatively high specificity but low sensitivity (Figure 2 ). It may result in false positive results therefore its clinical utility requires further investigations.
Our study had several limitations. Firstly, this was a single-centre study and the sample size was insufficient to come to final conclusions. Therefore, further prospective studies in a large population are needed. Moreover, it should be emphasised that multifactorial models accounted only for a small part of variability (<20%) of plasma concentrations of afamin and adropin; therefore, some other factors potentially affecting their concentrations should be search for. Our study did not involve patients with other than alcoholic liver cirrhosis; thus, it cannot be determined whether the observed relationships also regard some other group of patients.
Conclusions
The concentration of afamin decreases with the severity of alcoholic liver cirrhosis, which most likely results from impaired hepatic synthesis. Otherwise, the higher the stage of disease according to the Child-Pugh score, the higher the concentration of adropin. Further prospective studies are required to explain the role of both these proteins in alcoholic liver cirrhosis.
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